Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 1, 2016

Study Completion Date

August 1, 2016

Conditions
NauseaVomiting
Interventions
DRUG

aprepitant

aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.

DRUG

Ondansetron

Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.

Trial Locations (3)

27157

Wake Forest Baptist Health, Winston-Salem

85259-5499

Mayo Clinic Arizona, Scottsdale

05401

Fletcher Allen Health Care, Burlington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

Wake Forest University Health Sciences

OTHER

collaborator

Norris Cotton Cancer Center

OTHER

collaborator

University of Massachusetts, Worcester

OTHER

lead

University of Vermont

OTHER

NCT00970905 - Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy | Biotech Hunter | Biotech Hunter